$87.86—Stale · 2.1 years old
NASDAQ • Last print 2.1 years ago
$87.86—Stale · 2.1 years old
Immunomedics, Inc. (NASDAQ:IMMU) Receives $45.38 Average Target Price from Brokerages
Antibody Drug Conjugates (ADC) Market (COVID-19 Impact Analysis) 2020 Size, Share, Emerging Trends, Sales Revenue, Key Players Analysis, Opportunity Assessment || Seattle Genetics, Genentech, Pfizer, Novartis AG, F. Hoffmann-LA Roche
Immunomedics, Inc. (NASDAQ:IMMU) Shares Acquired by Canada Pension Plan Investment Board
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Immunomedics : Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer | MarketScreener
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer | MarketScreener
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
Immunomedics : Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers | MarketScreener
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers | MarketScreener
Stocks jump at the open on vaccine, merger news
3 ETFs To Play Gilead's $21B Immunomedics Takeover
Gilead Acquires Cancer-Drug Maker -- WSJ | MarketScreener
Gilead Reaches Deal to Buy Immunomedics for $21 Billion -- 5th Update | MarketScreener
Gilead reaches $21 billion deal for Immunomedics
Gilead Reaches Deal to Buy Immunomedics for $21 Billion--4th Update | MarketScreener
Gilead to buy cancer drugmaker Immunomedics in $21 billion deal
Gilead nears deal to buy Immunomedics for more than $20 billion
Gilead near deal to buy Immunomedics for more than $20 billion
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports
Immunomedics, Inc. (NASDAQ:IMMU) Shares Acquired by State Board of Administration of Florida Retirement System
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
AstraZeneca bets up to $6 billion on new Daiichi cancer drug